Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast

Annals of Clinical and Laboratory Science

Volumn 37, Issue 2, 2007, Pages 127-134

  Steinman, Sharon ^a   Wang, Jianmin ^b   Bourne, Patricia ^a   Yang, Qi ^a   Tang, Ping ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; Cytokeratin; DCIS; EGFR; ER ; HER 2 neu; IDC; PR

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEOPLASMS, MULTIPLE PRIMARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34248215798     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Tang P, Hajdu SI, Lyman GH. Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol 2007;19:63-67.
2. Dupond WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. NEJM 1985; 312:146-151.
3. Singletary E. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg 2002;194:201-216.
4. Buerger H. Otterbach F, Simon R, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Different genetic pathways in the evolutions of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999;189:521-526.
5. Kenemans P, Verstraeten RA, Verheijien RHM. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas 2004;49:34-43.
6. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005; 205:248-254.
7. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143:446-457.
8. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast. Evidence of multiple genetic pathways. J Pathol 1999: 187:396-402.
9. Shackney SE, Silverman JF. Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 2003;10: 278-290.
10. Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS. Adv Anat Pathol 2005;12:256-264.
11. Gasparini G, Longo R, Torino F, Morabito A. Therapy of breast cancer with molecular targeting agent. Ann Oncol 2005;16(Suppl 4):iv28-iv36.
12. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002; 198:458-467.
13. Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Gevenini G, Leoncini L, Tosi P. p53 mutant in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 2002;55:461-466.
14. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.
15. El-Rehim DMA, Pinder SE, Paish CE, Bell J, Blarney RW, Robertson JFR, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
16. Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci 2006;36:17-22.
17. Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI. Expression patterns of ER-α, PR, Her-2/neu, and EGFR in different cell origin subtypes of high-grade and non-high-grade ductal carcinoma in situ. Ann Clin Lab Sci 2006;36:137-143.
18. Holland F, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B. Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 1994;11:167-180.
19. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Slamon DJ. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-1157.
20. Cohen J. A coefficient of agreement for nominal scales. Educat Psychol Meas 1960;20,37-46.
21. Santini D, Ceccarelli C, Tardio ML, Taffurelli M, Marramo D. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. Appl Immunohistochem Mol Morphol 2002;10:29-33.
22. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999,187:272-290.
23. Hwang ES, Nyante SJ, Chen YY, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004;100:2562-2572.
24. Moore E, Magee H, Coyne J, Gorey T, Dervan PA. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J Pathol 199;187:403-409.
25. Zhou Q, Hopp T, Fuqua SA, Steeg PS. Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett 2001; 162:3-17.
26. Korshing E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Disest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533.
27. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/ progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193-197.
28. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906-920.
29. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 2006;97:135-144.
30. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-2484.
31. Giardina C, Serio G, Lepore G, Lettini T, Daiena M, Pennella A, D'Evadita-Valente T, Ricco R. Pure ductal carcin-oma in situ and in situ component of invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res 2003;22:279-288.
32. Park K, Han S, Kim HJ, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histolopathol 2006;48:702-707.
33. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002,196:280-286.
34. Lacroix M, Toillon RA, Leclercq G. Stable "portrait" of breast tumors during progression: data from biology, pathology, and genetics. Endocrine-Related Cancer 2004;11:497-522.
35. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her-2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005,25:1719-1723.
36. Jo BH, Chun YK. Heterogeneity of invasive ductal carcinoma: proposal for a hypothelical classification. J Korean Med Sci 2006;21:460-468.
37. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer. Breast Cancer Res Treat 1994;32:5-12.
38. Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS Suppl 2003;108:1-67.